Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  mitoxantrone hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 30052004, NCT00196768
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NOPHO-DBH-AML2012, 2012-002934-35, NCT01828489
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (=60) With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: PALG-AML2012, NCT02072811
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: Under 16
Sponsor: Other
Protocol IDs: 2010001, NCT02200978
Study of Crenolanib in Combination Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 19-13/ARO-007, NCT02298166
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 12 to 21
Sponsor: NCI, Other
Protocol IDs: AAML1331, NCI-2014-02266, U10CA180886, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2215-CL-0301, 2015-000140-42, NCT02421939
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 07-154, NCT00660036
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CAMN107YCA03T, NCT01222143
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 2652.00, NCI-2012-02224, 2652, P30CA015704, NCT01729845
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC 542, L 10, 819, NCT01842672
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2734.00, NCI-2013-02465, 2734, P30CA015704, NCT02044796
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFZ008, 2014-001633-84, NCT02303821
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GMI-1271-201, NCT02306291
Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AMLSG-R1, NCT00744081
Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: RJH-2011-RefactoryAML-SCT, NCT01496547
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: L-10,442, NCT01513603
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 20 to 75
Sponsor: Other
Protocol IDs: SMC2011-11-102-001, NCT01578343
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: ALLR18, NCT01700946
Start Over